Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris - PubMed (original) (raw)
Comparative Study
. 2015 Jan;172(1):244-52.
doi: 10.1111/bjd.13343. Epub 2014 Nov 30.
Affiliations
- PMID: 25132294
- DOI: 10.1111/bjd.13343
Comparative Study
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
R Gniadecki et al. Br J Dermatol. 2015 Jan.
Abstract
Background: Drug survival (time to drug discontinuation) has recently emerged as an important parameter reflecting the long-term therapeutic performance in a real-life setting. Biologic drug survival in psoriasis is mainly limited by a gradual loss of efficacy over time. Previous studies have been limited by small patient population size and short observation times and yielded discrepant survival times for different biologics.
Objectives: To calculate the long-term drug survival for adalimumab, etanercept, infliximab and ustekinumab in a large cohort of real-life patients with psoriasis vulgaris and to analyse the factors that influence drug survival.
Patients and methods: Data were extracted from the prospective registry DERMBIO covering all patients with psoriasis vulgaris treated with biologic agents in the academic centres in Denmark. Drug survival was analysed using the Kaplan-Meier method. The influence of different covariates on drug survival was analysed by Cox regression.
Results: Included in the analysis were 1867 treatment series (adalimumab n = 774, etanercept n = 449, infliximab n = 253, ustekinumab n = 391) administered in 1277 patients for up to 10 years. Drug survival was significantly longer for ustekinumab than for anti-tumour necrosis factor (TNF)-α agents (P < 0·001). Etanercept had the shortest survival time [median survival 30 months, 95% confidence interval (CI) 25·1-34·9] whereas adalimumab and infliximab had comparable survival rates (59 months, 95% CI 45·6-72·4; 44 months, 95% CI 33-54·9, respectively). Survival was longer in men [odds ratio (OR) 1·51, 95% CI 1·31-1·74 vs. women] and in patients who had not previously received any biologic agent (OR 1·24, 95% CI 1·05-1·46). Loss of efficacy accounted for 67% of all drug discontinuations.
Conclusions: Ustekinumab has a significantly longer drug survival than the anti-TNF-α agents. Switching from one biologic to another is associated with an impairment of drug survival. Preventing loss of efficacy is a major area of medical need in the biologic therapy of psoriasis and the strategies that improve drug survival should be further investigated.
© 2014 British Association of Dermatologists.
Similar articles
- Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R, Kragballe K, Dam TN, Skov L. Gniadecki R, et al. Br J Dermatol. 2011 May;164(5):1091-6. doi: 10.1111/j.1365-2133.2011.10213.x. Epub 2011 Apr 11. Br J Dermatol. 2011. PMID: 21219290 - Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, Giunta A, Vena GA, Chimenti S, Girolomoni G. Esposito M, et al. Br J Dermatol. 2013 Sep;169(3):666-72. doi: 10.1111/bjd.12422. Br J Dermatol. 2013. PMID: 23647206 - Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M, Pagès C, Aubin F, Delaporte E, Descamps V, Lok C, Beylot-Barry M, Séneschal J, Dubertret L, Morand JJ, Dréno B, Bachelez H; Groupe Français de Recherche sur le Psoriasis. Viguier M, et al. Br J Dermatol. 2012 Aug;167(2):417-23. doi: 10.1111/j.1365-2133.2012.10940.x. Epub 2012 Jun 11. Br J Dermatol. 2012. PMID: 22413927 - Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J, Burden AD. Leman J, et al. Br J Dermatol. 2012 Nov;167 Suppl 3:12-20. doi: 10.1111/j.1365-2133.2012.11209.x. Br J Dermatol. 2012. PMID: 23082811 Review. - Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K, Burden AD, Eaton JN, Hawkins NS. Reich K, et al. Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11. Br J Dermatol. 2012. PMID: 21910698 Review.
Cited by
- Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO).
Armstrong AW, Riedl E, Brunner PM, Piaserico S, Visser WI, Haustrup N, Konicek BW, Kadziola Z, Nunez M, Brnabic A, Schuster C. Armstrong AW, et al. Acta Derm Venereol. 2024 Sep 5;104:adv40556. doi: 10.2340/actadv.v104.40556. Acta Derm Venereol. 2024. PMID: 39235051 Free PMC article. - Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.
Strunz PP, Englbrecht M, Risser LM, Witte T, Froehlich M, Schmalzing M, Gernert M, Schmieder A, Bartz-Bazzanella P, von der Decken C, Karberg K, Gauler G, Wurth P, Späthling-Mestekemper S, Kuhn C, Vorbrüggen W, Heck J, Welcker M, Kleinert S. Strunz PP, et al. Rheumatol Int. 2024 Oct;44(10):2057-2066. doi: 10.1007/s00296-024-05671-9. Epub 2024 Aug 13. Rheumatol Int. 2024. PMID: 39136784 Free PMC article. - Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A, González-Cantero A, Khattri S, Muzy G, Malatestinic WN, Lampropoulou A, Feely M, See SK, Mert C, Blauvelt A. Armstrong A, et al. Dermatol Ther (Heidelb). 2024 Apr;14(4):933-952. doi: 10.1007/s13555-024-01136-w. Epub 2024 Mar 23. Dermatol Ther (Heidelb). 2024. PMID: 38521874 Free PMC article. - Traditional Chinese Medicine Shi-Bi-Man ameliorates psoriasis via inhibiting IL-23/Th17 axis and CXCL16-mediated endothelial activation.
Zhang C, Cao X, Zhao L, Ni Z, Du H, Qu J, Zhu J, Sun H, Sun Y, Ouyang Z. Zhang C, et al. Chin Med. 2024 Mar 1;19(1):38. doi: 10.1186/s13020-024-00907-z. Chin Med. 2024. PMID: 38429819 Free PMC article. - Drug Utilization and Measurement of Medication Adherence: A Real World Study of Psoriasis in Italy.
Mucherino S, Rafaniello C, Serino M, Zinzi A, Trama U, Capuano A, Menditto E, Orlando V. Mucherino S, et al. Pharmaceutics. 2023 Nov 21;15(12):2647. doi: 10.3390/pharmaceutics15122647. Pharmaceutics. 2023. PMID: 38139989 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical